Therefore, a third generation agent, Ponatinib (IclusigTM; ARIAD Pharmaceuticals, Cambridge, MA, U.S.A.)[31,32] was designed as a pan-inhibitor of BCR-ABL including the BCR-ABLT315I mutation and has shown exciting results in CML patients who harbor the BCR-ABLT315I mutation [33,34]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.